LIfT BioSciences

LIfT Biosciences is a biotech bringing to market a first-in-class alpha neutrophil cell therapy that overcomes the limitations of current therapies in solid tumours by destroying tumours both directly and indirectly. LIfTs Immunomodulatory Alpha Neutrophils (IMANs) turn the tumour microenvironment against the tumour as they recruit the rest of the immune system to destroy the tumour to give a durable response and lasting immunity. The patented breakthrough N-LIfT platform is produced from a patented process using exceptional stem cells (iPSC or HSC), a proprietary enhancement media and genetic engineering (e.g. CARs). The resulting CAR-IMAN cells give cancer patients potentially hundreds...

Oncology,cell therapy,solid tumours,first-in-class,unique,neutrophils,curative,pancreatic,lung,and biotech

Lift biosciences operates in the Biotechnology research industry.

Lift biosciences's revenue is 11m - 100m

Lift biosciences has 11 - 50 employees.